FilingReader Intelligence
3SBio secures Pfizer alliance with HK$785m share subscription
July 24, 2025 at 05:02 PM UTC•By FilingReader AI
3SBio Inc.'s license agreement with Pfizer for PD-1/VEGF bispecific antibody came into effect, giving Pfizer exclusive development rights in China with potential worldwide expansion. 3SBio expects up to $150m in fees.
Pfizer will subscribe for 31.1m new 3SBio shares at HK$25.21 each, totaling HK$785m at a 17% discount to market price.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1530•Hong Kong Exchange
News Alerts
Get instant email alerts when 3SBio Inc publishes news
Free account required • Unsubscribe anytime